Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
05 May 2022 - 9:00PM
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader,
today announced that the company will host a conference call and
live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review
business updates and its first quarter 2022 financial results.
A live webcast will be available under "News & Events" in
the Investors & Media section of the company's website at
www.orchard-tx.com. The conference call can be accessed by dialing
+1 (866) 374-5140 (toll-free) or +1 (404) 400-0571 (toll) and using
the passcode 71474312. A replay of the webcast will be archived on
the Orchard website following the presentation.
About Orchard
At Orchard Therapeutics, our vision is to end the devastation
caused by genetic and other severe diseases. We aim to do this by
discovering, developing and commercializing new treatments that tap
into the curative potential of hematopoietic stem cell (HSC) gene
therapy. In this approach, a patient’s own blood stem cells are
genetically modified outside of the body and then reinserted, with
the goal of correcting the underlying cause of disease in a single
treatment.
In 2018, the company acquired GSK’s rare disease gene therapy
portfolio, which originated from a pioneering collaboration between
GSK and the San Raffaele Telethon Institute for Gene Therapy in
Milan, Italy. Today, Orchard has a deep pipeline spanning
pre-clinical, clinical and commercial stage HSC gene therapies
designed to address serious diseases where the burden is immense
for patients, families and society and current treatment options
are limited or do not exist.
Orchard has its global headquarters in London and U.S.
headquarters in Boston. For more information, please visit
www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Availability of Other Information About
Orchard
Investors and others should note that Orchard communicates with
its investors and the public using the company website
(www.orchard-tx.com), the investor relations website
(ir.orchard-tx.com), and on social media
(Twitter and LinkedIn), including but not limited to
investor presentations and investor fact sheets, U.S.
Securities and Exchange Commission filings, press releases,
public conference calls and webcasts. The information that Orchard
posts on these channels and websites could be deemed to be material
information. As a result, Orchard encourages investors, the media,
and others interested in Orchard to review the information that is
posted on these channels, including the investor relations website,
on a regular basis. This list of channels may be updated from time
to time on Orchard’s investor relations website and may include
additional social media channels. The contents of Orchard’s website
or these channels, or any other website that may be accessed from
its website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Contacts
Investors
Renee LeckDirector, Investor Relations+1
862-242-0764Renee.Leck@orchard-tx.com
Orchard Therapeutics (NASDAQ:ORTX)
Historical Stock Chart
From Apr 2024 to May 2024
Orchard Therapeutics (NASDAQ:ORTX)
Historical Stock Chart
From May 2023 to May 2024